Hemcare - multiple myeloma learning programme
24 Jun 2017
Hemcare - multiple myeloma learning programme
Enasidenib in mIDH relapsed and refractory AML
The role of patient advocates in trial design, participation
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL
ESMO ranking of the clinical benefits of new drugs
Cancer and the workplace
The recent past and near future of drug approvals in Europe
Informed patients are empowered patients
Gastrectomy and oral drug prescription
Improving care for cancer patients
Managing cancer and living meaningfully